

The American Journal of Medicine®

THE 5TH INTERNATIONAL SUCRALFATE RESEARCH CONFERENCE

1

Introduction

Daniel Hollander

2

Effect of Sucralfate on Human Gastric Bicarbonate Secretion and Local Prostaglandin E₂ Metabolism

Christopher J. Shorrock, Wynne D.W. Rees

5

Sucralfate Interactions with Gastric Mucus

Clifford Tasman-Jones, Gail Morrison, Lindy Thomsen, Mark Vanderwee

10

Protection of Rat Gastric Mucosa by Sucralfate: Effects of Luminal Stasis and of Inhibition of Prostaglandin Synthesis

Gerald P. Morris, Catherine M. Keenan, Wallace K. MacNaughton, John L. Wallace, Todd E. Williamson

17

Prostanoid Production in Post-Gastrectomy Gastritis: Influence of Sucralfate

Agustin Payno, Jose M. Lopez-Novoa, Diego Rodriguez-Puyol

21

Sucralfate in the Prevention of Porcine Experimental Peptic Ulceration

Graham N. Stapleton, I.N. Marks, A. Joan Fourie, Heather McLeod, Rosemary Hickman, Anwar Mall, John Terblanche

23

Pathways of Gastrointestinal Protection and Repair: Mechanisms of Action of Sucralfate

Sandor Szabo, Daniel Hollander

32

Epidermal Growth Factor in the Gastroprotective and Ulcer-Healing Actions of Sucralfate in Rats

Stanislaw J. Konturek, Toman Brzozowski, Wladystaw Bielanski, Zygmunt Warzecha, Danuta Drozdowicz

38

Effects of Food and Sucralfate on the Pharmacokinetics of Naproxen and Ketoprofen in Humans

Gilles Caillé, Patrick du Souich, Jean Guy Besner, Pierre Gervais, Manon Vézina

45

Comparison of Sucralfate and Ranitidine in the Treatment of Chronic Nonerosive Gastritis: A Randomized, Multicenter Trial

Mario Guslandi

49

Effect of Sucralfate and Cimetidine on Rheumatoid Patients with Active Gastroduodenal Lesions Who Are Taking Nonsteroidal Anti-Inflammatory Drugs: A Pilot Study

Hugh A. Shepherd, David Fine, Keith Hillier, Richard Jewell, Nigel Cox

55

Comparison of Sucralfate and Ranitidine in Gastroprotection against Alcohol in Humans

Stanislaw J. Konturek, Tomasz Mach, Jan W. Konturek, Josef Bogdal, Jerzy Stachura

60

Effect of Sucralfate and Cimetidine on Duodenal Ulcer-Associated Antral Gastritis and *Campylobacter pylori*

Wai Mo Hui, Shiu Kum Lam, Joana Ho, Irene Ng, Wan Yee Lau, Frank J. Branicki, Ching Lung Lai, Anna Suk Fong Lok, Matthew Mar Tai Ng, John Fok, Gar-Pang Poon, Tat Kuen Choi

66

Lack of Gastric Mucosal Protection by Sucralfate during Long-Term Aspirin Ingestion in Humans

Anthony I. Stern, Fiona Ward, William Sievert

70

Sucralfate in the Treatment of Gastritis: A Review

Colin L. Smith

The American Journal of Medicine®

THE 5TH INTERNATIONAL SUCRALFATE RESEARCH CONFERENCE

1

Introduction

Daniel Hollander

2

Effect of Sucralfate on Human Gastric Bicarbonate Secretion and Local Prostaglandin E₂ Metabolism

Christopher J. Shorrock, Wynne D.W. Rees

5

Sucralfate Interactions with Gastric Mucus

Clifford Tasman-Jones, Gail Morrison, Lindy Thomsen, Mark Vanderwee

10

Protection of Rat Gastric Mucosa by Sucralfate: Effects of Luminal Stasis and of Inhibition of Prostaglandin Synthesis

Gerald P. Morris, Catherine M. Keenan, Wallace K. MacNaughton, John L. Wallace, Todd E. Williamson

17

Prostanoid Production in Post-Gastrectomy Gastritis: Influence of Sucralfate

Agustin Payno, Jose M. Lopez-Novoa, Diego Rodriguez-Puyol

21

Sucralfate in the Prevention of Porcine Experimental Peptic Ulceration

Graham N. Stapleton, I.N. Marks, A. Joan Fourie, Heather McLeod, Rosemary Hickman, Anwar Mall, John Terblanche

23

Pathways of Gastrointestinal Protection and Repair: Mechanisms of Action of Sucralfate

Sandor Szabo, Daniel Hollander

32

Epidermal Growth Factor in the Gastroprotective and Ulcer-Healing Actions of Sucralfate in Rats

Stanislaw J. Konturek, Toman Brzozowski, Wladystaw Bielanski, Zygmunt Warzecha, Danuta Drozdowicz

38

Effects of Food and Sucralfate on the Pharmacokinetics of Naproxen and Ketoprofen in Humans

Gilles Caillé, Patrick du Souich, Jean Guy Besner, Pierre Gervais, Manon Vézina

45

Comparison of Sucralfate and Ranitidine in the Treatment of Chronic Nonerosive Gastritis: A Randomized, Multicenter Trial

Mario Guslandi

49

Effect of Sucralfate and Cimetidine on Rheumatoid Patients with Active Gastroduodenal Lesions Who Are Taking Nonsteroidal Anti-Inflammatory Drugs: A Pilot Study

Hugh A. Shepherd, David Fine, Keith Hillier, Richard Jewell, Nigel Cox

55

Comparison of Sucralfate and Ranitidine in Gastroprotection against Alcohol in Humans

Stanislaw J. Konturek, Tomasz Mach, Jan W. Konturek, Josef Bogdal, Jerzy Stachura

60

Effect of Sucralfate and Cimetidine on Duodenal Ulcer-Associated Antral Gastritis and *Campylobacter pylori*

Wai Mo Hui, Shiu Kum Lam, Joana Ho, Irene Ng, Wan Yee Lau, Frank J. Branicki, Ching Lung Lai, Anna Suk Fong Lok, Matthew Mar Tai Ng, John Fok, Gar-Pang Poon, Tat Kuen Choi

66

Lack of Gastric Mucosal Protection by Sucralfate during Long-Term Aspirin Ingestion in Humans

Anthony I. Stern, Fiona Ward, William Sievert

70

Sucralfate in the Treatment of Gastritis: A Review

Colin L. Smith

73

Sucralfate versus Cimetidine in the Treatment of Reflux Esophagitis in Children

Federico Argüelles-Martin, Fernando Gonzalez-Fernandez, Myrna Grace Gentiles

77

Combination Therapy of Sucralfate and Cimetidine, Compared with Sucralfate Monotherapy, in Patients with Peptic Reflux Esophagitis

Raudwyn H. Schotborgh, Wilhelm Hameeteman, Wilhelm Dekker, D.M. v.d. Boomgaard, Gerard H. van Olfen, Max Schrijver, G.D.C. Vosmaer, Guido N.J. Tytgat

81

Prevention of Upper Gastrointestinal Bleeding in Long-Term Ventilated Patients: Sucralfate versus Ranitidine

Anton N. Laggner, Kurt Lenz, Wolfgang Base, Wilfred Druml, Bruno Schneeweiss, Georg Grimm

85

Side Effects of Stress Bleeding Prophylaxis

Michael Tryba

94

Sucralfate versus Ranitidine in the Treatment of Gastric Ulcer: Randomized Clinical Results in Short-Term and Maintenance Therapy

Jose Manuel Herreras-Gutierrez, Leonardo Pardo, Jose Luis Segu

98

Sucralfate and Ranitidine in the Treatment of Acute Duodenal Ulcer: Healing and Relapse

Hans R. Koelz, Fred Halter, Ulcer Study Group

104

Sucralfate Suspension 1 g Four Times per Day in the Short-Term Treatment of Active Duodenal Ulcer

François Martin

108

Twice-Daily Sucralfate Dosing to Heal Acute Duodenal Ulcer

Timothy Schubert, The Multicenter Study Group

113

Two Daily Doses of Sucralfate or Cimetidine in the Healing of Gastric Ulcer: A Comparative Randomized Study

Alan Hjortrup, Lars Bo Svendsen, Henning Beck, Jack Hoffmann, Marianne Schroeder

116

Comparative Study of Sucralfate versus Cimetidine in the Treatment of Acute Gastroduodenal Ulcer: Randomized Trial with 667 Patients

Jean-François Rey, Bernard Legras, Alain Verdier, Fernand Vicari, Claude Gorgeat

122

Implications of Sucralfate-Induced Ulcer Healing and Relapse

Shiu Kum Lam

127

Sucralfate Tablets 1 g Twice a Day for the Prevention of Duodenal Ulcer Recurrence

T. Edward Bynum, Gary G. Koch

133

Sucralfate as Maintenance Treatment for the Prevention of Duodenal Ulcer Recurrence

Matti Paakkonen, Sakari Aukee, Esko Janatuinen, Juhani Lahtinen, Frank Laxen, Matti Olsen, Pekka Pikkarainen, Eero Poikolainen

136

A Maintenance Regimen of Sucralfate 2 g at Night for Reduced Relapse Rate in Duodenal Ulcer Disease: A One-Year Follow-Up Study

I.N. Marks, Andrew H. Girdwood, Keith A. Newton, Stephen J. O'Keefe, Francesco Marotta, Wendy Lucke

141

Differences in Mucosal Appearances and in Relapse Rates in Duodenal Ulceration Treated with Sucralfate or Cimetidine

Frank I. Tovey, Elizabeth M. Husband, Yiu Chu Yiu, Louise Baker, Graham McPhail, A. Paul Jayaraj, Michael R. Lewin, Charles G. Clark

145

Acid-Secretory Response and Parietal Cell Sensitivity in Patients with Duodenal Ulcer before and after Treatment with Sucralfate or Ranitidine

I.N. Marks, Geradine O. Young, Nel A. Tigler-Wybrandt, Sharon Bridger, Keith A. Newton

148

Sucralfate Maintenance Therapy in Duodenal Ulcer Disease: A Review

Terry D. Bolln

152

Peptic Disease Therapy: Sucralfate and Cytoprotection in the 1980s

Daniel Hollander

VOLUME 87 (2A) AUGUST 16, 1989

CLINICAL SETTINGS FOR SELECTIVE ALPHA-ADRENERGIC RECEPTOR INHIBITION: RATIONALE AND MANAGEMENT STRATEGIES

2A-1S

Introduction

Stanley H. Taylor

2A-2S

Clinical Pharmacotherapeutics of Doxazosin

Stanley H. Taylor

2A-12S

Structure and Function of Alpha-Adrenergic Receptors

Paul A. Insel

2A-19S

Mechanisms Contributing to the Arrhythmogenic Influences of Alpha₁-Adrenergic Stimulation in the Ischemic Heart

Peter B. Corr, Guy P. Heathers, Kathryn A. Yamada

2A-26S

Alpha-Adrenoceptor Inhibitors in the Treatment of Benign Prostatic Hyperplasia

Roger S. Kirby

2A-31S

Controlling Drug Effects through Improved Oral Formulations: The Pharmacokinetics of the Prazosin Gastrointestinal Therapeutic System

Joseph T. DiPiro

2A-36S

Pharmacologic Basis for the Use of Doxazosin in the Treatment of Essential Hypertension

Michael J. Davey

2A-45S

Efficacy and Safety of Minipress XL, a New Once-a-Day Formulation of Prazosin

Walter Singleton, Robert K. Dix, Lisa Monsen, Donna Moisey, Marcia Levenstein, Denise F. Bottiglieri, Lewis Silver

2A-53S

Selective Alpha₁-Adrenergic Blockade, Lipids, and Coronary Heart Disease Risk: Considerations in the Treatment of Mild Hypertension

Robert M. Graham

2A-57S

Review of the Effects of Doxazosin, a New Selective Alpha₁-Adrenergic Inhibitor, on Lipoproteins in Patients with Essential Hypertension

James L. Pool, Addison A. Taylor, Edward B. Nelson

2A-62S

Management of Hypertension: Potential Trade-Offs on Coronary Risk

Richard H. Grimm, Jr., John M. Flack

2A-66S

Closing Remarks

Stanley H. Taylor

Volume 87 (3A) September 4, 1989

HEPATITIS B: THE DISEASE AND ITS PREVENTION

3A-1S

Introduction

F. Blaine Hollinger

3A-2S

Feasibility of Controlling or Eradicating the Hepatitis B Virus

Baruch S. Blumberg

3A-5S

Seroepidemiology of Hepatitis B Virus Infection in the United States: 1976 to 1980

Geraldine M. McQuillan, Timothy R. Townsend, Howard A. Fields, Margaret Carroll, Marie Leahy, B. Frank Polk

3A-11S

Hepatitis B Infection in the United States: Recent Trends and Future Strategies for Control

Mark A. Kane, Miriam J. Alter, Stephen C. Hadler, Harold S. Margolis

3A-14S

Summary of Safety and Efficacy Data on a Yeast-Derived Hepatitis B Vaccine

Francis E. André

3A-21S

Vaccination against Hepatitis B in Homosexual Men: A Review

Christian Gollav, Peter Plot

3A-26S

Protective Efficacy of a Recombinant Deoxyribonucleic Acid Hepatitis B Vaccine in Institutionalized Mentally Handicapped Clients

Pierre Van Damme, Robert Vranckx, Assad Safary, Francis E. André, Andre Meheus

3A-30S

Immunogenicity of a Yeast-Derived Hepatitis B Vaccine in Hemodialysis Patients

Miguel Bruguera, Manuel Cremades, José Luis Rodicio, José Maria Alcazar, Arturo Oliver, Gerardo Del Rio, Rafael Esteban-Mur

3A-33S

Hepatitis B Vaccination of Neonates and Children

Myron J. Tong

3A-36S

Factors Influencing the Immune Response to Hepatitis B Vaccine, Booster Dose Guidelines, and Vaccine Protocol Recommendations

F. Blaine Hollinger

3A-41S

Concluding Remarks

F. Blaine Hollinger

VOLUME 87 (3B) SEPTEMBER 11, 1989

ROLE OF ANTITHROMBIN III IN COAGULATION DISORDERS: STATE-OF-THE-ART REVIEW

3B-1S

Introduction

Robert D. Rosenberg

3B-2S

Biochemistry of Heparin Antithrombin Interactions, and the Physiologic Role of This Natural Anticoagulant Mechanism

Robert D. Rosenberg

3B-10S

Serpin Receptor 1: A Hepatic Receptor That Mediates the Clearance of Antithrombin III-Proteinase Complexes

Salvatore V. Pizzo

3B-15S

Molecular Genetics of Inherited Antithrombin III Deficiencies

Edward V. Prochownik

3B-19S

Antithrombin Inactivation by Neutrophil Elastase Requires Heparin

Robert E. Jordan, Richard M. Nelson, Jaleh Kilpatrick, James O. Newgren, Pamela C. Esmon, Michael A. Fournel

3B-23S**Purification and Large-Scale Preparation of Antithrombin III**

David L. Hoffman

3B-27S**Efficacy of Antithrombin III Supplementation in Animal Models of Fulminant *Escherichia coli* Endotoxemia or Bacteremia**

Thomas E. Emerson, Jr., Michael A. Fournel, Thomas B. Redens, Fletcher B. Taylor, Jr.

3B-34S**Congenital Antithrombin III Deficiency: Incidence and Clinical Features**

Jack Hirsh, Franco Piovella, Mario Pini

3B-39S**Congenital Antithrombin III Deficiency: Insights into the Pathogenesis of the Hypercoagulable State and its Management Using Markers of Hemostatic System Activation**

Kenneth A. Bauer, Robert D. Rosenberg

3B-44S**Acquired Antithrombin III Deficiency: Laboratory Diagnosis, Incidence, Clinical Implications, and Treatment with Antithrombin III Concentrate**

Harry R. Büller, Jan W. ten Cate

3B-49S**Neonatal Antithrombin III Deficiency**

Marilyn J. Manco-Johnson

3B-53S**Clinical Experience with Antithrombin III Concentrate in Treatment of Congenital and Acquired Deficiency of Antithrombin**

Richard S. Schwartz, Kenneth A. Bauer, Robert D. Rosenberg, Elin J. Kavanaugh, Diane C. Davies, David A. Bogdanoff, The Antithrombin III Study Group

3B-61S**Antithrombin III Prophylaxis of Venous Thromboembolic Disease after Total Hip or Total Knee Replacement**

Charles W. Francis, Vincent D. Pellegrini, Jr., Carl M. Harris, Victor J. Marder

3B-67S**Conclusion**

Robert D. Rosenberg

VOLUME 87 (3C) SEPTEMBER 18, 1989

SECOND INTERNATIONAL SYMPOSIUM ON RILMENIDINE**UPDATE ON HYPERTENSION****3C-1S****Alpha₂-Adrenoceptors and Endothelium-Derived Relaxing Factor**

Paul M. Vanhoutte, Virginia M. Miller

3C-6S**Investigation of Alpha₂-Adrenoceptors in Humans**

Morris J. Brown

3C-10S**New Concepts on the Central Regulation of Blood Pressure: Alpha₂-Adrenoceptors and "Imidazoline Receptors"**

Pascal Bousquet, Josiane Feldman, Eduardo Tiberica, Giampiero Bricca, Annick Molines, Monique Dantenwill, Alain Belcourt

ANTIHYPERTENSIVE TREATMENT AND RILMENIDINE: A NEW INSIGHT**3C-14S****Recent Advances in the Pharmacology of Rilmenidine**

Jean-Louis Montastruc, Isabelle Macquin-Mavier, Marie-Antoinette Tran, Christine Damase-Michel, Elisabeth Koenig-Berard, Philippe Valet

3C-18S**Pharmacokinetics of Rilmenidine**

Patrick Genissel, Norbert Bromet

3C-24S**Rilmenidine: A Novel Antihypertensive Agent**

Michel E. Safar

ANTIHYPERTENSIVE TREATMENT AND AT-RISK POPULATIONS**3C-30S****Treatment of Hypertension in Diabetic Patients**

André E. Lambert, Muteba Mpoy, Bernard Vandeleene, Jean-Marie Ketelsiegers

3C-34S**Bronchial Effects of Alpha₂-Adrenoceptor Agonists and of Other Antihypertensive Agents in Asthma**

Anh Tuan Dinh Xuan, Alain Lockhart

3C-38S**Hypertension in the Elderly**

John L.C. Dall

3C-41S**Acceptability of Rilmenidine and Long-Term Surveillance of Plasma Concentrations in Hypertensive Patients with Renal Insufficiency**

Robert L. Lins, Ronald Daelemans, Max Dratwa, Dirk Verbeelen, Jacques Sennesael, Brigitte Brisgand, Norbert Lameire

PHYSIOLOGIC TOLERANCE AND COMPLIANCE: CHARACTERISTICS OF RILMENIDINE**3C-46S****Effort Blood Pressure Control in the Course of Antihypertensive Treatment**

Oreste de Divitiis, Salvatore Di Somma, Vincenzo Liguori, Maurizio Pettito, Carmine Magnotta, Mario Ausiello, Nicola Natale, Marcello Brignoli, Maurizio Galderisi

3C-57S**Antihypertensive Drugs and Baroreflex Sensitivity: Effects of Rilmenidine**

Dean W.G. Harron

3C-63S**Renal Excretory Actions of Antihypertensive Agents: Effects of Rilmenidine**

William P. Leary

3C-67S**Rilmenidine and Vigilance: Review of Clinical Studies**

Florence Mahieux

CONCLUSION

3C-73S

Conclusion

Jean Paul Fillastre, Paul M. Vanhoutte

VOLUME 87 (4A) OCTOBER 16, 1989

**SIMVASTATIN: A ONCE-A-DAY TREATMENT
FOR HYPERCHOLESTEROLEMIA**

4A-1S

**Simvastatin: A Once-a-Day Treatment for
Hypercholesterolemia: An Introduction**

Richard J. Havel

4A-2S

Rationale for Cholesterol Lowering

Richard J. Havel

4A-5S

**The Epidemiology of Hypercholesterolemia:
A Global Perspective**

Peter W.F. Wilson

4A-14S

**Overview of Clinical Trials of Cholesterol
Lowering in Relationship to Epidemiologic
Studies**

Herman A. Tyroler

4A-20S

**Management of Hypercholesterolemia:
Approach to Diet and Drug Therapy**

Evan A. Stein

4A-28S

**Animal Safety and Toxicology of Simvastatin and
Related Hydroxy-methyl-glutaryl-Coenzyme A
Reductase Inhibitors**

Ronald J. Gerson, James S. MacDonald, Albert W. Alberts,
Douglas J. Kornbrust, James A. Majka, R. John Stubbs, Delwin L.
Bokelman

4A-39S

Efficacy and Tolerability of Simvastatin (MK-733)

Anton F.H. Stalenhoef, Marc J.T.M. Mol, Paul M.J. Stuyt

4A-44S

Simvastatin: The Clinical Profile

J. Findlay Walker

4A-47S

**Comparison of Low-Dose Simvastatin and
Gemfibrozil in the Treatment of Elevated Plasma
Cholesterol: A Multicenter Study**

Matti J. Tikkanen, Tomas S. Bocanegra, J. Findlay Walker, Tom Cook,
The Simvastatin Study Group

4A-54S

**Cost Effectiveness of Cholesterol-Lowering
Therapy in The Netherlands: Simvastatin versus
Cholestyramine**

Leon L. Martens, Frans F.H. Rutten, D. William Erkelens,
Carl A.P.L. Ascoop

4A-59S

**Simvastatin: A Once-a-Day Treatment for
Hypercholesterolemia: A Summary**

Richard J. Havel

